0.25
0.5
0.75
1.25
1.5
1.75
2
Clinical, pathological and molecular characterisation of C9orf72-ALS leads to identification of novel therapeutic targets
Published on Sep 22, 20171156 Views
Johnathan Cooper-Knock works as a clinical research fellow at SITRAN, the Sheffield Institute for Translational Neuroscience in Sheffield, UK. His interest is in studying the changes to gene expressio
Related categories
Chapter list
Clinical, pathological and molecular characterisation of C9orf72-ALS leads to identification of novel therapeutic targets00:00
Plan for talk00:22
Paper01:00
C9orf72 neuropathology02:03
C9orf72 and parkinsonism03:15
C9orf72 and multiple sclerosis - 105:10
C9orf72 and multiple sclerosis - 206:55
Untitled07:36
Effect of repeat length on c9orf72 transcription08:25
C9orf72 and RNA foci09:52
RNA foci and RRM-containing proteins10:21
Relative distribution of sense and antisense RNA foci - 111:33
Relative distribution of sense and antisense RNA foci - 212:04
Cellular distribution of RNA foci and TDP-4313:11
Conclusions from RNA foci work14:11
Recent papers14:41
Gene expression profiling in motor neurons15:33
Next steps...16:58
Thanks - 118:52
Thanks - 219:15